

# A Janet Hoogstraate

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2727896/publications.pdf>

Version: 2024-02-01

29  
papers

1,416  
citations

430874

18  
h-index

501196

28  
g-index

29  
all docs

29  
docs citations

29  
times ranked

1804  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of Heterologous Effects of Travel Vaccines in Colorectal Cancer: A Database Study and a Cautionary Tale. , 2022, 1, 531-537.		0
2	Travel vaccines are strongly associated to reduced mortality in prostate cancer patients - a real effect or residual confounding?. Vaccine, 2022, 40, 3797-3801.	3.8	1
3	Substrate and method dependent inhibition of three ABC-transporters (MDR1, BCRP, and MRP2). European Journal of Pharmaceutical Sciences, 2017, 103, 70-76.	4.0	27
4	Optimizing DMPK Properties: Experiences from a Big Pharma DMPK Department. Current Drug Metabolism, 2016, 17, 253-270.	1.2	7
5	Functional ATP-Binding Cassette Drug Efflux Transporters in Isolated Human and Rat Hepatocytes Significantly Affect Assessment of Drug Disposition. Drug Metabolism and Disposition, 2014, 42, 448-458.	3.3	42
6	Cytochrome P450 Inhibitory Properties of Common Efflux Transporter Inhibitors. Drug Metabolism and Disposition, 2014, 42, 441-447.	3.3	35
7	Prediction of In Vivo Rat Biliary Drug Clearance from an In Vitro Hepatocyte Efflux Model. Drug Metabolism and Disposition, 2014, 42, 459-468.	3.3	13
8	The Impact of Solute Carrier (SLC) Drug Uptake Transporter Loss in Human and Rat Cryopreserved Hepatocytes on Clearance Predictions. Drug Metabolism and Disposition, 2014, 42, 469-480.	3.3	32
9	Early Identification of Clinically Relevant Drug Interactions With the Human Bile Salt Export Pump (BSEP/ABCB11). Toxicological Sciences, 2013, 136, 328-343.	3.1	133
10	An evidence-based oral hygiene education program for nursing staff. Nurse Education in Practice, 2011, 11, 256-259.	2.6	14
11	Regional transport and metabolism of ropivacaine and its CYP3A4 metabolite PPX in human intestine. Journal of Pharmacy and Pharmacology, 2010, 55, 963-972.	2.4	27
12	A Survey of Attitudes and Perceptions Toward Oral Hygiene Among Staff at a Geriatric Nursing Home. Geriatric Nursing, 2010, 31, 435-440.	1.9	17
13	Evaluation of dental hygiene education for nursing home staff. Journal of Advanced Nursing, 2010, 66, 345-349.	3.3	26
14	Dental hygiene education for nursing staff in a nursing home for older people. Journal of Advanced Nursing, 2010, 66, 1273-1279.	3.3	31
15	Correct assessment of new compounds using in vivo screening models can reduce false positives. Drug Discovery Today, 2009, 14, 89-94.	6.4	13
16	Dental Hygiene Education for Nursing Staff. Geriatric Nursing, 2009, 30, 329-333.	1.9	21
17	A Systematic Review of the Preventive Effect of Oral Hygiene on Pneumonia and Respiratory Tract Infection in Elderly People in Hospitals and Nursing Homes: Effect Estimates and Methodological Quality of Randomized Controlled Trials. Journal of the American Geriatrics Society, 2008, 56, 2124-2130.	2.6	289
18	Prediction and Identification of Drug Interactions with the Human ATP-Binding Cassette Transporter Multidrug-Resistance Associated Protein 2 (MRP2; ABCC2). Journal of Medicinal Chemistry, 2008, 51, 3275-3287.	6.4	119

#	ARTICLE	IF	CITATIONS
19	Gene and Protein Expression of P-Glycoprotein, MRP1, MRP2, and CYP3A4 in the Small and Large Human Intestine. <i>Molecular Pharmaceutics</i> , 2007, 4, 252-257.	4.6	172
20	Scintillation proximity assay for measuring uptake by the human drug transporters hOCT1, hOAT3, and hOATP1B1. <i>Analytical Biochemistry</i> , 2007, 366, 117-125.	2.4	15
21	Direct gas measurements indicate that the novel cyclooxygenase inhibitor AZD3582 is an effective nitric oxide donor in vivo. <i>British Journal of Pharmacology</i> , 2005, 145, 679-687.	5.4	7
22	AZD3582 increases heme oxygenase-1 expression and antioxidant activity in vascular endothelial and gastric mucosal cells. <i>European Journal of Pharmaceutical Sciences</i> , 2005, 25, 229-235.	4.0	19
23	A common pathway of nitric oxide release from AZD3582 and glyceryl trinitrate. <i>European Journal of Pharmaceutical Sciences</i> , 2004, 21, 331-335.	4.0	15
24	Characterization of jejunal absorption and apical efflux of ropivacaine, lidocaine and bupivacaine in the rat using in situ and in vitro absorption models. <i>European Journal of Pharmaceutical Sciences</i> , 2004, 21, 553-560.	4.0	71
25	COX-inhibiting nitric oxide donators (CINODs) – a new paradigm in the treatment of pain and inflammation. <i>Inflammopharmacology</i> , 2003, 11, 423-428.	3.9	16
26	Oral gingival delivery systems from chitosan blends with hydrophilic polymers. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2003, 55, 47-56.	4.3	87
27	Sequencing and tissue distribution of the canine MRP2 gene compared with MRP1 and MDR1. <i>Toxicology</i> , 2001, 156, 81-91.	4.2	55
28	In vivo buccal delivery of the peptide drug buserelin with glycodeoxycholate as an absorption enhancer in pigs. <i>Pharmaceutical Research</i> , 1996, 13, 1233-1237.	3.5	47
29	Diffusion rates and transport pathways of fluorescein isothiocyanate (FITC)-labeled model compounds through buccal epithelium. <i>Pharmaceutical Research</i> , 1994, 11, 83-89.	3.5	65